Skip to main content
Premium Trial:

Request an Annual Quote

Dionex Posts 13 Percent Increase in Q1 Revenues, 31 Percent Jump in HPLC Sales

Premium

Chromatography systems vendor Dionex posted revenues of $102.9 million for the first quarter of its fiscal year 2011, a 13 percent increase over last year's first-quarter figure of $90.7 million driven in part by a 31 percent increase in sales of its HPLC devices.

In a statement, Dionex CEO Frank Whitney noted that HPLC sales were particularly strong in the Asia-Pacific market, and that the company had seen increased demand from its life science customers compared to the first quarter of 2010.

He projected 2011 sales in the range of $452 million to $460 million based on improving economic conditions and the recent release of products, including Dionex's new UHPLC+ line.

The company posted profits of $10.9 million for the quarter, up 6 percent over $10.3 million in the first quarter of 2010.

It spent $8 million on R&D, up 11 percent from $7.1 million a year ago, and reported holdings of $77 million in cash and cash equivalents.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.